William Beck, MD
Ophthalmology · Newton, KSNPI 1104894070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $554 and has fallen 67.9% since, to $178 in 2025.
Across 148 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$490
- Amgen$421
- AbbVie$399
- Biohaven Pharmaceutical Holding Company Ltd.$172
- Daiichi Sankyo Inc.$120
- Apellis Pharmaceuticals, Inc.$111
- plus $648 from 22 others
Across 19 payments — averaging $3277.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$49K
- AbbVie$14K
What the payments were for
- Food & beverage$2,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $490 |
| Amgen | 24 | $421 |
| AbbVie(2 entities) | 25 | $399 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $172 |
| Daiichi Sankyo Inc. | 8 | $120 |
| Apellis Pharmaceuticals, Inc. | 1 | $111 |
| Biohaven Pharmaceuticals, Inc. | 6 | $110 |
| Pfizer | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $52 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $41 |
| Lilly USA, LLC | 3 | $37 |
| GSK | 2 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Merck | 2 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $27 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Pacira Therapeutics, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Novartis | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Bayer | 1 | $11 |
| Ultragenyx Pharmaceutical Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$111
How this compares
$2,362 in reported general payments places this provider in the 65th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 43 | $27,384 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $11,041 |
| VyzultaLatanoprostene Bunod | 20 | $8,727 |
| LumiganBimatoprost | 12 | $2,945 |
| Alphagan PBrimonidine Tartrate | 11 | $2,066 |
| Latanoprost | 372 | $1,874 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 21 | $1,651 |
| Prednisolone Acetate | 52 | $1,575 |
| Timolol Maleate | 244 | $1,456 |
| Brimonidine Tartrate | 47 | $1,012 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 59 | $706 |
| ValacyclovirValacyclovir Hcl | 12 | $535 |
| Acyclovir | 36 | $367 |
| Dorzolamide Hcl | 11 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $399 | $32,39666 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $12 | $36736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Newton
- Daniel DurrieOverland Park$974K
- John DoaneLeawood$496K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Blake CooperLenexa$100K
- Miranda BisharaPrairie Village$45K
- Jeff WongskhaluangOlathe$42K
- Michael EllisLenexa$38K
- Matthew SniegowskiLeawood$22K
- Michele RigginsWichita$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.